The Asia Pacific Veterinary Vaccines Market is projected to experience significant growth, with an expected market size of approximately US$ 4,520.4 million by 2031, up from US$ 2,556.7 million in 2024. This growth translates to a compound annual growth rate (CAGR) of 8.5% from 2025 to 2031.
Governments across the Asia Pacific are implementing policies to promote the widespread adoption of veterinary vaccination programs, which are crucial for controlling infectious and zoonotic diseases affecting animals. The rising incidence of chronic zoonotic infections that impact both animals and humans is further fueling the demand for effective veterinary vaccines. Additionally, growing awareness regarding animal welfare and disease prevention is expected to enhance the outlook for the Asia Pacific veterinary vaccines market, positioning the region as a significant growth area in the global veterinary vaccine landscape.
For instance, in March 2024, Zoetis announced the acquisition of a 21-acre production facility in Melbourne to expand its operations and increase future capacity for developing vaccines for various animals, including sheep, cattle, dogs, cats, and horses. Similarly, in December 2023, Indian Immunologicals Limited (IIL) began constructing a new veterinary vaccine manufacturing facility in Genome Valley, Hyderabad, with an investment of Rs.700 crore (approximately US$ 82.74 million). This facility aims to produce the Foot and Mouth Disease vaccine and a combination vaccine for Foot and Mouth Disease and Haemorrhagic Septicaemia, creating over 750 jobs.
In 2024, Vaksindo Vietnam Co Ltd inaugurated a state-of-the-art veterinary vaccine factory in Yên My II Industrial Park, Hung Yên Province, which is certified to GMP-WHO standards and produces various vaccines targeting pigs, cattle, and poultry. These expansions not only increase supply to meet global demand but also reduce production costs through economies of scale. Local manufacturing facilities ensure faster distribution and lower reliance on imports, particularly in developing countries like India.
Private pharmaceutical companies in Japan also play a crucial role in developing vaccines tailored to the livestock industry's needs. For example, in 2021, Meiji Seika Pharma launched a vaccine aimed at reducing mortality rates and clinical symptoms of Swine edema disease in pigs.
Executive Summary and Market Analysis
The veterinary vaccines market in the Asia Pacific region is categorized into several segments, including key countries such as China, Japan, India, Australia, South Korea, and other nations in the region. The market is anticipated to grow considerably during the forecast period, driven by robust government support and proactive initiatives from market players aimed at enhancing animal health management. Countries like Australia, India, and South Korea are identified as having substantial growth potential due to advancements in vaccine development, improvements in veterinary healthcare infrastructure, and increasing livestock populations.Governments across the Asia Pacific are implementing policies to promote the widespread adoption of veterinary vaccination programs, which are crucial for controlling infectious and zoonotic diseases affecting animals. The rising incidence of chronic zoonotic infections that impact both animals and humans is further fueling the demand for effective veterinary vaccines. Additionally, growing awareness regarding animal welfare and disease prevention is expected to enhance the outlook for the Asia Pacific veterinary vaccines market, positioning the region as a significant growth area in the global veterinary vaccine landscape.
Strategic Insights
Market Segmentation Analysis
The Asia Pacific Veterinary Vaccines Market is segmented based on various criteria:
- By Technology: The market is divided into Live Attenuated Vaccines, Inactivated Vaccines, Recombinant Vaccines, Toxoid Vaccines, and Others. Live Attenuated Vaccines are projected to hold the largest market share in 2024.
- By Animal Type: The market is categorized into Companion Animals and Livestock & Poultry, with Livestock and Poultry expected to dominate the market share in 2024.
- By Companion Animals: This segment includes Dogs, Cats, Horses, and Others, with Dogs anticipated to hold the largest share.
- By Livestock and Poultry: This includes Chicken, Cattle, and Others, where Chicken is expected to lead the market.
- By Route of Administration: The market is segmented into Intramuscular, Subcutaneous, and Others, with Intramuscular administration projected to hold the largest share.
- By End User: This includes Veterinary Hospitals, Veterinary Clinics, and Others, with Veterinary Hospitals expected to dominate the market.
Market Outlook
The expansion of manufacturing plants represents a significant growth opportunity for the veterinary vaccines market. This expansion addresses critical issues such as production scalability, cost reduction, and improved accessibility of vaccines in the region. The increasing demand for veterinary vaccines, driven by rising pet ownership, livestock management needs, and international disease prevention initiatives, has prompted producers to invest in new facilities and upgrade existing ones to enhance production capacity.For instance, in March 2024, Zoetis announced the acquisition of a 21-acre production facility in Melbourne to expand its operations and increase future capacity for developing vaccines for various animals, including sheep, cattle, dogs, cats, and horses. Similarly, in December 2023, Indian Immunologicals Limited (IIL) began constructing a new veterinary vaccine manufacturing facility in Genome Valley, Hyderabad, with an investment of Rs.700 crore (approximately US$ 82.74 million). This facility aims to produce the Foot and Mouth Disease vaccine and a combination vaccine for Foot and Mouth Disease and Haemorrhagic Septicaemia, creating over 750 jobs.
In 2024, Vaksindo Vietnam Co Ltd inaugurated a state-of-the-art veterinary vaccine factory in Yên My II Industrial Park, Hung Yên Province, which is certified to GMP-WHO standards and produces various vaccines targeting pigs, cattle, and poultry. These expansions not only increase supply to meet global demand but also reduce production costs through economies of scale. Local manufacturing facilities ensure faster distribution and lower reliance on imports, particularly in developing countries like India.
Country Insights
The Asia Pacific Veterinary Vaccines Market is further segmented by country, with Japan holding the largest market share in 2024. The Japanese government has long recognized the importance of animal health, implementing vaccination programs for diseases such as avian influenza and Foot and Mouth Disease (FMD). The Ministry of Agriculture, Forestry, and Fisheries (MAFF) in Japan has established strict surveillance and biosecurity measures to support these vaccination efforts.Private pharmaceutical companies in Japan also play a crucial role in developing vaccines tailored to the livestock industry's needs. For example, in 2021, Meiji Seika Pharma launched a vaccine aimed at reducing mortality rates and clinical symptoms of Swine edema disease in pigs.
Company Profiles
Key players in the Asia Pacific Veterinary Vaccines Market include Merck & Co Inc, Boehringer Ingelheim International GmbH, Ceva Santé Animale, Zoetis Inc, Elanco Animal Health Inc, Virbac SA, Neogen Corp, Hester Biosciences Ltd, HIPRA SA, and Biovac LTD. These companies are employing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their product offerings and increase market share.Table of Contents
1. Introduction
2. Executive Summary
3. Research Methodology
4. Veterinary Vaccines Market Landscape
5. Asia Pacific Veterinary Vaccines Market - Key Market Dynamics
6. Veterinary Vaccines Market - Asia Pacific Market Analysis
7. Asia Pacific Veterinary Vaccines Market Revenue Analysis - by Technology
8. Asia Pacific Veterinary Vaccines Market Revenue Analysis - by Animal Type
9. Asia Pacific Veterinary Vaccines Market Revenue Analysis - by Companion
10. Asia Pacific Veterinary Vaccines Market Revenue Analysis - by Livestock And Poultry
11. Asia Pacific Veterinary Vaccines Market Revenue Analysis - by Route Of Administration
12. Asia Pacific Veterinary Vaccines Market Revenue Analysis - by End User
13. Asia Pacific Veterinary Vaccines Market - Country Analysis
15 Industry Landscape
16 COMPANY PROFILES
17. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies
The List of Companies - Asia Pacific Veterinary Vaccines MarketMerck & Co Inc
Boehringer Ingelheim International GmbH
Ceva Sante Animale
Zoetis Inc
Elanco Animal Health Inc
Virbac SA
Neogen Corp
Hester Biosciences Ltd
HIPRA SA
Biovac LTD
